4D Molecular Therapeutics Inc
FDMT10.500USD
-0.420-3.85%
Fechamento 11/07, 16:00（ET）Cotações atrasadas em 15 min
490.35MValor de mercado
PerdaP/L TTM
Mais detalhes de 4D Molecular Therapeutics Inc Empresa
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Informações de 4D Molecular Therapeutics Inc
Código da empresaFDMT
Nome da Empresa4D Molecular Therapeutics Inc
Data de listagemDec 11, 2020
CEODr. David Kirn, M.D.
Número de funcionários227
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 11
Endereço5858 Horton Street #455
CidadeEMERYVILLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94608
Telefone15105052680
Sitehttps://4dmoleculartherapeutics.com/
Código da empresaFDMT
Data de listagemDec 11, 2020
CEODr. David Kirn, M.D.
Executivos da empresa 4D Molecular Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Mr. Ashoo Gupta
Mr. Ashoo Gupta
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
45.66K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Nancy Miller-Rich
Ms. Nancy Miller-Rich
Independent Director
Independent Director
--
--
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Simms
Mr. Christopher (Chris) Simms
Chief Commercial Officer
Chief Commercial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Mr. Ashoo Gupta
Mr. Ashoo Gupta
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
45.66K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
15.00K
0.00%
Netherlands
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 8 de nov
Atualizado em: sáb, 8 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BVF Partners L.P.
9.91%
RA Capital Management, LP
9.77%
Goldman Sachs & Company, Inc.
8.01%
Novo Holdings A/S
6.80%
BlackRock Institutional Trust Company, N.A.
6.67%
Outro
58.84%
Investidores
Investidores
Proporção
BVF Partners L.P.
9.91%
RA Capital Management, LP
9.77%
Goldman Sachs & Company, Inc.
8.01%
Novo Holdings A/S
6.80%
BlackRock Institutional Trust Company, N.A.
6.67%
Outro
58.84%
Tipos de investidores
Investidores
Proporção
Investment Advisor
19.79%
Investment Advisor/Hedge Fund
19.57%
Hedge Fund
17.68%
Venture Capital
17.25%
Research Firm
14.76%
Individual Investor
3.95%
Pension Fund
0.15%
Sovereign Wealth Fund
0.12%
Bank and Trust
0.11%
Outro
6.63%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
353
39.94M
73.19%
-18.33M
2025Q2
351
46.37M
100.09%
-13.01M
2025Q1
358
46.38M
99.71%
-13.16M
2024Q4
357
49.60M
107.13%
-13.93M
2024Q3
350
60.77M
117.85%
-4.39M
2024Q2
340
60.30M
117.01%
-2.54M
2024Q1
324
59.47M
116.84%
+10.27M
2023Q4
284
45.54M
106.82%
-1.53M
2023Q3
275
45.63M
108.12%
-4.94M
2023Q2
263
44.82M
109.79%
-393.70K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BVF Partners L.P.
4.63M
9.91%
+68.00K
+1.49%
Jun 30, 2025
RA Capital Management, LP
4.56M
9.77%
--
--
Jun 30, 2025
Goldman Sachs & Company, Inc.
3.74M
8.01%
-7.99K
-0.21%
Jun 30, 2025
Novo Holdings A/S
2.00M
4.28%
+50.00K
+2.56%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.12M
6.67%
-415.30K
-11.76%
Jun 30, 2025
The Vanguard Group, Inc.
2.74M
5.86%
-20.82K
-0.75%
Jun 30, 2025
Janus Henderson Investors
1.75M
3.76%
-137.53K
-7.27%
Jun 30, 2025
Kirn (David)
1.66M
3.55%
-360.00
-0.02%
Apr 24, 2025
Federated MDTA LLC
1.65M
3.54%
+411.45K
+33.10%
Jun 30, 2025
Millennium Management LLC
1.48M
3.18%
-150.26K
-9.20%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
Federated Hermes MDT Small Cap Core ETF
0.59%
iShares Micro-Cap ETF
0.07%
Harbor Human Capital Factor US Small Cap ETF
0.07%
iShares Health Innovation Active ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Ver Mais
Federated Hermes MDT Small Cap Core ETF
Proporção0.59%
iShares Micro-Cap ETF
Proporção0.07%
Harbor Human Capital Factor US Small Cap ETF
Proporção0.07%
iShares Health Innovation Active ETF
Proporção0.05%
ProShares Ultra Nasdaq Biotechnology
Proporção0.04%
Invesco Nasdaq Biotechnology ETF
Proporção0.04%
iShares Biotechnology ETF
Proporção0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.03%
Avantis US Small Cap Equity ETF
Proporção0.03%
iShares Russell 2000 Value ETF
Proporção0.02%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
